Pfizer supports Israeli CytoReason and signs AI-based research agreement

Pfizer supports Israeli CytoReason and signs AI based research agreement

Pharmaceutical giant Pfizer is investing $20 million in Israeli company CytoReason, a developer of computational disease models for drug discovery and development, as part of a broader deal worth up to $110 million over the next five years, the companies announced on Tuesday. The agreement builds on an existing multi-year cooperation agreement dating from 2019 … Read more